Achieve Life Sciences (NASDAQ:ACHV) Issues Earnings Results, Beats Estimates By $0.11 EPS

Posted by Stanley Muller on May 12th, 2026

Achieve Life Sciences (NASDAQ:ACHV – Get Free Report) issued its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.11, FiscalAI reports.

Here are the key takeaways from Achieve Life Sciences’ conference call:

Achieve said its recent $180 million private placement, with up to $174 million more from milestone warrants, gives the company a strong capital base to pursue approval and launch plans.
The company expects an FDA complete response letter tied to issues at a prior third-party manufacturer and plans to resubmit the NDA in Q4 2026 with Adare Pharma Solutions as the primary U.S. commercial supply partner.
Management highlighted encouraging clinical and mechanistic data for cytisinicline, including selective receptor activity that may help explain its low nausea rates and strong efficacy in hard-to-treat patients who previously used varenicline or bupropion.
Achieve is moving ahead with an independent commercial launch strategy and has added experienced leaders from Verona Pharma, including a new commercial SVP and sales leadership for the field force.
The company reiterated plans to advance its vaping program, saying it hopes to initiate the ORCA-V2 phase III trial this year while continuing to work with FDA on timelines and trial design.

Achieve Life Sciences Price Performance

Shares of ACHV stock traded up $0.25 on Tuesday, hitting $5.84. 1,924,237 shares of the stock traded hands, compared to its average volume of 968,806. The company has a debt-to-equity ratio of 0.52, a current ratio of 4.39 and a quick ratio of 4.39. Achieve Life Sciences has a 52 week low of $2.00 and a 52 week high of $6.15. The firm has a 50 day simple moving average of $3.98 and a two-hundred day simple moving average of $4.44. The firm has a market cap of $310.70 million, a price-to-earnings ratio of -4.49 and a beta of 2.25.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on ACHV shares. Canaccord Genuity Group set a $13.00 price target on Achieve Life Sciences and gave the company a “buy” rating in a report on Monday, April 20th. Weiss Ratings downgraded Achieve Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday. Wall Street Zen raised Achieve Life Sciences from a “strong sell” rating to a “sell” rating in a research report on Saturday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $12.00 price target on shares of Achieve Life Sciences in a research report on Thursday, April 16th. Two investment analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $14.67.

Check Out Our Latest Stock Analysis on ACHV

Institutional Investors Weigh In On Achieve Life Sciences

Institutional investors and hedge funds have recently bought and sold shares of the business. AQR Capital Management LLC bought a new position in shares of Achieve Life Sciences in the first quarter worth about $32,000. Qube Research & Technologies Ltd purchased a new position in Achieve Life Sciences in the 2nd quarter worth approximately $232,000. Raymond James Financial Inc. lifted its holdings in Achieve Life Sciences by 57.1% in the 2nd quarter. Raymond James Financial Inc. now owns 295,058 shares of the biopharmaceutical company’s stock worth $667,000 after purchasing an additional 107,218 shares in the last quarter. Jane Street Group LLC bought a new stake in shares of Achieve Life Sciences during the second quarter valued at approximately $159,000. Finally, Bank of America Corp DE lifted its holdings in shares of Achieve Life Sciences by 39.9% in the second quarter. Bank of America Corp DE now owns 33,731 shares of the biopharmaceutical company’s stock worth $76,000 after buying an additional 9,617 shares in the last quarter. 33.52% of the stock is owned by institutional investors.

Achieve Life Sciences Company Profile

(Get Free Report)

Achieve Life Sciences, Inc (NASDAQ: ACHV) is a clinical-stage biotechnology company dedicated to the development and commercialization of cytisinicline, a plant-derived alkaloid for smoking cessation. The company’s mission is to offer a novel, evidence-based therapy that addresses the global need for effective and well-tolerated smoking cessation options. Achieve focuses its efforts on advancing the clinical profile of cytisinicline through rigorous development programs and regulatory engagement.

Cytisinicline (formerly marketed as Tabex® in Europe) acts as a nicotinic acetylcholine receptor partial agonist, helping reduce withdrawal symptoms and nicotine cravings.